8/4/2021 8:42:04 AM
Alterity:US Patent To Expand Portfolio Of Compounds For Neurodegenerative Diseases Including Alzheimer's And Parkinson's
7/15/2021 9:55:23 AM
Alterity : ATH434 Reduces ?–synuclein Related Neurodegeneration In Murine Model Of Multiple System Atrophy
7/1/2021 7:51:09 AM
Alterity Therapeutics Granted New US Patent Targeting Neurodegenerative Diseases Incl Alzheimer's And Parkinson's
6/23/2021 9:25:43 AM
Alterity Therapeutics Receives European Union Regulatory Guidance For ATH434 Phase 2 Trial
2/9/2021 8:56:41 AM
Alterity Announces Funding From Michael J. Fox Foundation For ATH434 Dose Optimization
1/7/2021 8:19:50 AM
Alterity Therapeutics Appoints David Stamler As CEO
8/3/2020 10:06:57 PM
Alterity : New Data Independently Confirms And Extends Laboratory Findings And Expands Safety Profile Of ATH434